摘要
Abstract
Nectin-4 is a tumor-associated cell adhesion molecule that is highly expressed in various gynecologic malignancies,such as cervical,ovarian,and endometrial cancers,and is closely related to tumor development,progression,and prognosis.In recent years,Nectin-4 has emerged as an important target for the development of antibody-drug conjugate(ADC).Enfortumab vedotin(EV),an ADC targeting Nectin-4,has been approved by the US Food and Drug Administration(FDA)for the treatment of urothelial cancer.However,no clinical trials have directly evaluated the application of EV in gynecologic malignancies.Nevertheless,multiple studies have shown that the high expression of Nectin-4 in gynecologic malignancies may make it a potential therapeutic target.In addition,domestic ADCs such as 9MW2821 and SHR-A2102 are currently in clinical trials and are expected to offer new treatment options for gynecologic malignancies.Future studies on the efficacy and safety of Nectin-4-targeted ADCs in gynecologic malignancies are highly anticipated and may bring new hope to patients with drug resistant or advanced disease.关键词
连接蛋白/生殖器肿瘤,女(雌)性/免疫轭合物/分子靶向治疗/Nectin-4/恩诺单抗Key words
Nectins/Genital neoplasms,female/Immunoconjugates/Molecular targeted therapy/Nectin-4/Enfortumab vedotin
